$95.05
Value $7.1B
KNSA and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$95.05
Value $7.1B
$137.78
Value $341B
Kiniksa Pharmaceuticals International (KNSA) has a market value of $7.1B and Merck & Company (MRK) $341B. Over the last year, with dividends, KNSA moved +129.6% and MRK +52.7%. The P/E is 64.4 for KNSA and 138.9 for MRK. Dividend yield: KNSA none, MRK 2.47%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
KNSA$7.1B
MRK$341B
MRK is 48 times KNSA
Revenue, 12 months
KNSA$946M
MRK$67.4B
MRK is 71 times KNSA
Net income, 12 months
KNSA$110M
MRK$2.5B
MRK is 22 times KNSA
Operating margin
KNSA13.8%
MRK–
ROIC
KNSA15.9%
MRK3.9%
12.0 points apart
P/E
KNSA64.4
MRK138.9
MRK is 2.2 times KNSA
Dividend yield
KNSA0.0%
MRK2.5%
2.5 points apart
5-year return
KNSA+637.4%
MRK+94.3%
543.1 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
KNSA+637.4%
MRK+94.3%
| Period | KNSAWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 17, 2025 | +129.6%Price +129.6% | +52.7%Price +48.4% |
| 3 years since November 17, 2023 | +505.0%+82.2% a yearPrice +505.0% | +48.4%+14.1% a yearPrice +35.4% |
| 5 years since November 17, 2021 | +637.4%+49.1% a yearPrice +637.4% | +94.3%+14.2% a yearPrice +66.8% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
KNSAKiniksa Pharmaceuticals InternationalMRKMerck & Company
| Price | $95.05 | $137.78 |
|---|---|---|
| Market value | $7.1B | $341B |
| Enterprise value (EV) | $6.5B | $385B |
| P/E | 64.4 | 138.9 |
| P/E, 5-year median | 55.0 | 14.8 |
| P/B | 9.9 | 7.6 |
| EV/EBIT | 49.7 | 80.8 |
| Free cash flow yield | 2.8% | 4.3% |
| Revenue, 12 months | $946M | $67.4B |
|---|---|---|
| Net income, 12 months | $110M | $2.5B |
| Free cash flow, 12 months | $197M | $14.7B |
| Earnings per share, 12 months | $1.31 | $0.98 |
| Revenue growth, year on year | 60.1% | 1.3% |
| Revenue growth a year, past | +104.8%over 4 years | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | 90.2% | 71.8% |
|---|---|---|
| Operating margin | 13.8% | – |
| Net margin | 11.6% | 3.6% |
| ROIC | 15.9% | 3.9% |
| ROE | 17.8% | 5.2% |
| Cash | $569M | $9.7B |
|---|---|---|
| Total debt | $7.9M | $53.8B |
| Net debt / EBITDA | -4.3 | 5.7 |
| Interest cover | – | 2.4× |
| Dividend yield | – | 2.5% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.5% |
| Shareholder yield | – | 4.0% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($341B) is about 48.3 times Kiniksa Pharmaceuticals International ($7.1B), at today's prices.
Since November 17, 2021, KNSA's price moved +637.4% and MRK's +66.8%. With dividends: KNSA +637.4% (+49.1% a year), MRK +94.3% (+14.2% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for Kiniksa Pharmaceuticals International and 2.47% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
At today's price, the P/E is 64.4 for KNSA and 138.9 for MRK. The median of the last five years was 55.0 and 14.8, which shows where each stands against its own past.
Over the last twelve months, the net margin was 11.6% for Kiniksa Pharmaceuticals International and 3.6% for Merck & Company, and the operating margin 13.8% and –. Revenue was $946M and $67.4B.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.